title: PI3K inhibitors as potential therapeutics for autoimmune disease.
abstract: Aberrant overactivation of the immune system can give rise to chronic and persistent self-attack, culminating in autoimmune disease. This is currently managed therapeutically using potent immunosuppressive and anti-inflammatory drugs. Class I phosphoinositide 3-kinases (PI3Ks) have been identified as ideal therapeutic targets for autoimmune diseases given their wide-ranging roles in immunological processes. Recent studies into the function of selective PI3K inhibitors in vitro and in vivo have yielded encouraging results, allowing progression into the clinic. Here, we review their recent progress across a range of autoimmune diseases.
authors.affiliation: Department of Pharmacy & Pharmacology, University of Bath, Claverton Down BA2 7AY, UK.
authors.forename: Jennifer
authors.initials: J
authors.lastname: Ball
authors.affiliation: Department of Pharmacy & Pharmacology, University of Bath, Claverton Down BA2 7AY, UK.
authors.forename: Sophie
authors.initials: S
authors.lastname: Archer
authors.affiliation: Department of Pharmacy & Pharmacology, University of Bath, Claverton Down BA2 7AY, UK. Electronic address: S.G.Ward@bath.ac.uk.
authors.forename: Stephen
authors.initials: S
authors.lastname: Ward
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*
chemical_list: D004791:Enzyme Inhibitors; D000081082:Phosphoinositide-3 Kinase Inhibitors; D047428:Protein Kinase Inhibitors